Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer

Cancer

Volumn 110, Issue 8, 2007, Pages 1697-1707

  Mudduluru, Giridhar ^a   Medved, Fabian ^a   Grobholz, Rainer ^b   Jost, Camela ^a   Gruber, Anette ^a   Leupold, Joerg H ^a   Post, Stefan ^a   Jansen, Aaron ^c   Colburn, Nancy H ^c   Allgayer, Heike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenoma; Colorectal cancer; Prognosis; Programmed cell death 4; Protein kinase B

Indexed keywords

NUCLEAR PROTEIN; PROGRAMMED CELL DEATH 4 PROTEIN; PROTEIN KINASE B; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPLASM; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOMA; APOPTOSIS REGULATORY PROTEINS; COLON; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-AKT; RECTUM; RNA-BINDING PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 35248889933     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22983     Document Type: Article

References (30)

1. Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA. 1999;96:14037-14042.
2. Yang HS, Jansen AP, Nair R, et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene. 2001;20:669-676.
3. Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 2005;65:6034-6041.
4. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene. 1995;166:297-301.
5. Onishi Y, Kizaki H. Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors. Biochem Biophys Res Commun. 1996;228:7-13.
6. Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B. Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T cells. J Immunol. 1998;161:3493-3500.
7. Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 1999;49:1067-1077.
8. Soejima H, Miyoshi O, Yoshinaga H. Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet. 1999;87:113-114.
9. Chen Y, Knosel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol. 2003;200:640-646.
10. Kang MJ, Ahn HS, Lee JY, Matsuhashi S, Park WY. Up-regulation of PDCD4 in senescent human diploid fibroblasts. Biochem Biophys Res Commun. 2002;293:617-621.
11. Zhang Z, DuBois RN. Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene. 2001;20:4450-4456.
12. Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol. 2004;287:1541-1546.
13. Lankat-Buttgereit B, Gregel C, Knolle A, Hasilik A, Arnold R, Goke R. Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II. Mol Cell Endocrinol. 2004;214:149-153.
14. Bitomsky N, Bohm M, Klempnauer KH. Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene. 2004;23:7484-7493.
15. Yang HS, Matthews CP, Clair T, et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol. 2006;26:1297-1306.
16. Yang HS, Cho MH, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH. A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol. 2004;24:3894-3906.
17. Yang HS, Jansen AP, Komar AA, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol. 2003;23:26-37.
18. Zakowicz H, Yang HS, Stark C, Wlodawer A, Laronde-Leblanc N, Colburn NH. Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. RNA. 2005;11:261-274.
19. Onishi Y, Hashimoto S, Kizaki H. Cloning of the TIS gene suppressed by topoisomerase inhibitors. Gene. 1998;215:453-459.
20. Schlichter U, Kattmann D, Appl H, Miethe J, Brehmer-Fastnacht A, Klempnauer KH. Identification of the myb-inducible promoter of the chicken Pdcd4 gene. Biochim Biophys Acta. 2001;1520:99-104.
21. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res. 2005;65:11282-11286.
22. Ossowski L, Clunie G, Masucci MT, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol. 1991;115:1107-1112.
23. Schewe DM, Leupold JH, Boyd DD, et al. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res. 2003;9:2267-2276.
24. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase-receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene. 2007;26:4550-4562.
25. Beyer BC, Heiss MM, Simon EH, et al. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer. 2006;106:1026-1035.
26. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle. 2006;5:1760-1771.
27. Dorrello NV, Peschiaroli A, Daniele G, Colburn NH, Sherman NE, Pagano M. Degradation of PDCD4 promotes protein translation and cell growth. Science. 2006;314:467-471.
28. Bohm M, Sawicka K, Siebrasse JP, Brehmer-Fastnacht A, Peters R, Klempnauer KH. The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA. Oncogene. 2003;22:4905-4910.
29. Ahmed NN, Franke TF, Bellacosa A, et al. The proteins encoded by c-Akt and v-Akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene. 1993;8:1957-1963.
30. Bellacosa A, Chan TO, Ahmed NN, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene. 1998;17:313-325.